Diabetes and obesity
Eloralintide and tirzepatide combination led to 23.3% weight loss in trial
In a 48-week phase 2 trial, the highest-dose eloralintide and tirzepatide combination was linked to 23.3% weight loss in adults with type 2 diabetes and overweight or obesity.

Adults with type 2 diabetes and overweight or obesity who received eloralintide with tirzepatide lost up to 23.3% of their body weight over 48 weeks in a phase 2 trial, according to results presented at the European Association for the Study of Diabetes annual meeting. The trial included 367 adults. The greatest weight loss was reported with eloralintide 9 mg plus tirzepatide 15 mg. Participants receiving tirzepatide 15 mg alone lost 14.8%.
The reports differ on discontinuations due to adverse events. Healio reported that less than 10% of adults in all arms discontinued the trial for this reason. MedPage Today reported that 27% in the highest-dose combination group discontinued treatment, compared with 2.9% in the tirzepatide-alone group. Healio also reported that gastrointestinal events were most common, and that 6.5% of participants had at least one serious adverse event.
The trial used two separate injections for the combination. Healio reported that Lilly plans to co-formulate the drugs into one injection for its upcoming phase 3 trial. MedPage Today reported Lilly plans to advance the combination into phase III development by the end of the year.


